CN105497167A - New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis - Google Patents
New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis Download PDFInfo
- Publication number
- CN105497167A CN105497167A CN201511022020.XA CN201511022020A CN105497167A CN 105497167 A CN105497167 A CN 105497167A CN 201511022020 A CN201511022020 A CN 201511022020A CN 105497167 A CN105497167 A CN 105497167A
- Authority
- CN
- China
- Prior art keywords
- radix ranunculi
- ranunculi ternati
- ulcerative colitis
- medical material
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a new application of radix ranunculi ternate, namely a new application of the radix ranunculi ternate in preparation of a preparation for treating and/or preventing ulcerative colitis, in particular to a new application of the radix ranunculi ternate in preparation of a medicine for treating and/or preventing the ulcerative colitis.
Description
Technical field
The present invention relates to the novelty teabag of Radix Ranunculi Ternati, particularly the novelty teabag of Radix Ranunculi Ternati polysaccharide, namely prepare the novelty teabag treated and/or prevented in ulcerative colitis medicine.
Background technology
Ulcerative colitis (UC) is a kind of chronic nonspecific inflammation disease occurring in coton and rectal, and its age of onset is comparatively light, is the trend increased year by year at the sickness rate of China.The etiology and pathogenesis of ulcerative colitis is still not clear, and the traditional Chinese medical science, from "Nei Jing", is gone through supplementing and explaination of generation doctor, is roughly based on void, holds concurrently and presss from both sides heat, wet, the stasis of blood.The interaction of the factors such as modern medicine is then thought that it is main and immune, infected, environment, heredity is relevant, it is impaired often to there is intestinal mucosal barrier in ulcerative colitis, antigen is caused to enter, immunity is excessively strengthened, thus causes series of symptoms clinically, normal with microthrombusis in patient's intestinal mucosa, thrombocytosis, platelet activation also starts immunoreation, causes the activation of cytokine, tumor necrosis factor, interleukin correlation factor, occurs the impaired performance of a series of intestinal mucosa.Research shows that in patients of ulcerative colitis body, pro-inflammatory cytokine level raises, and press down inflammatory cytokine levels and reduce, and the level raised becomes positive correlation with the order of severity of disease.
Ulcerative colitis is that a kind of cause of disease is complicated, the course of disease is very long, the state of an illness is changeable, cures the disease that difficulty is high, relapse rate is high, is classified as one of modern difficult treatment by World Health Organization (WHO).Current medicine mainly contains glucocorticoid, aminosalicyclic acid supplement and immunosuppressant etc., although this type of medicine is for basic research and the clinical treatment of colitis, but the problem such as have that adverse reaction rate is high, relapse rate is high and curative effect is not good enough, needs a kind of medicine for the treatment of ulcerative colitis safely and effectively so eager.
The main active of Chinese medicine Radix Ranunculi Ternati is Radix Ranunculi Ternati polysaccharide, saponin." chemical composition of Radix Ranunculi Ternati and Advance on Pharmacological Activities " " Chinese crude drug " research shows: Radix Ranunculi Ternati is mainly containing the compound such as flavonoid and glycoside, volatile oil, organic acid, containing seven compounds, be respectively the mixture, daucosterol, Palmic acid etc. of podocarpusflavone A, phthalic acid two, Heneicosane acid methyl ester, 5-methylol alkanoic acid methyl ester, 5 hydroxymethyl furfural, stigmasterol and sitosterol.Polysaccharide wherein contained by Radix Ranunculi Ternati, saponin have immunoregulatory effect, are considered to its effective ingredient.
Radix Ranunculi Ternati contains the number of chemical compositions such as Radix Ranunculi Ternati saponin, lactone, fatty acid, sterols, polysaccharide and trace element, has the effects such as excited immunocompetence, heat-clearing and toxic substances removing, detumescence, eliminating stagnation, sore-throat relieving, sterilization, anti-tumor activity.Known Radix Ranunculi Ternati can be used for the diseases such as treatment pulmonary tuberculosis, lymphoid tuberculosis, lymphosarcoma, scrofula.
Radix Ranunculi Ternati or Radix Ranunculi Ternati polysaccharide is not yet had to be used for the treatment of the relevant report of ulcerative colitis at present.
Summary of the invention
The object of this invention is to provide Radix Ranunculi Ternati and prepare the novelty teabag treated and/or prevented in ulcerative colitis medicine;
Another object of the present invention is to provide Radix Ranunculi Ternati extract and is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine;
Another object of the present invention is to provide Radix Ranunculi Ternati polysaccharide and is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine;
Another object of the present invention is to provide the preparation method of Radix Ranunculi Ternati polysaccharide.
The object of the invention is by following technical scheme realize:
Raw material sources of the present invention:
Radix Ranunculi Ternati: Radix Ranunculi Ternati system another name ram's horn grass, three loose grass, being the tuber of cohosh ranunculus ternatus, is annual herb plant, and cluster the little tuber of most meat, and tuber is ovoid or spindle, and top matter is hard, and likeness in form ram's horn, diameter is about 3-5mm.Ram's horn grass blade paving is loose, high 5-20cm, and multi-branched is more soft, most five maos.Basal leaf has long handle, and blade shape is changeable, and single leaf or 3 goes out compound leaf, long 5-40mm, wide 4-25mm, and lobule 2 is shallow to be split to 3 drastic cracks or repeatedly checking, end return sliver be obovate to line style, without hair; The long 6-11cm of petiole.Radix Ranunculi Ternati is mainly distributed in Guangxi, Taiwan, Jiangsu, zhejiang and other places, is born in Plain and wets meadow or wasteland, limit, field.Radix Ranunculi Ternati property is put down, and sweet in the mouth is pungent, warm, enters liver, lung two warp.The traditional Chinese medical science thinks that Radix Ranunculi Ternati has dissipating phlegm and resolving masses, removing toxic substances and promoting subsidence of swelling, the effects such as treatment Drug resistant pulmonary tubeculosis, malaria and lymphadenitis.
Research data both domestic and external shows, ulcerative colitis may be closely related with the immune system of intestinal, and cytokine plays an important role in the immune system process of body.In patients of ulcerative colitis body, pro-inflammatory cytokine level raises, and press down inflammatory cytokine levels and reduce, and the order of severity of the level raised and disease is proportionate.Along with the continuous progress of Protocols in Molecular Biology and basic research, scientists thinks that inflammatory cytokine IL-1, IL-6, IL-8, IL-17 and TNF-α etc. that mononuclear cell and macrophage produce has important function in enteritis regulation and control, and inflammatory inhibitive factor IL-1ra, IL-4, IL-10 then contend with the effect of inflammatory cytokine.Inventor finds in the therapeutic process of research ulcerative colitis, plant Radix Ranunculi Ternati particularly polysaccharide contained by Radix Ranunculi Ternati shows reduction pro-inflammatory cytokine level, raise the effect of inflammation T suppression cell factor level, achieve the remarkable improvement of intervention to ulcerative colitis pathogenesis and pathological symptom, thus effectively treat ulcerative colitis.
Interleukin (IL) topmostly in cytokine has multiple bioactive one group of lymphokine, and at transmission of information, activate with immunity moderation cell, mediation T, B cell reproduction restraint and in inflammatory reaction process, play important regulating action.
Interleukin-11 (IL-1) is a kind of cytokine with several functions, especially tackle cause of disease invasion time host response startup with development in play a crucial role, be the important regulatory factor that immunity starts with inflammation, can be produced by secretions such as mononuclear cell, mastocyte, smooth muscle cell and endotheliocytes.Studies have found that, after UC patient treatment, the content of the another kind of form IL-1 β of IL-1 obviously declines.IL-1 β can increase the cytokine that produced by macrophage as tumor necrosis factor-alpha, IL-6 and IL-8, neutrophilic granulocyte is assembled to inflammation part, enters intestinal diseased region, thus cause a series of intestinal pathological changes.
Interleukin-22 (IL-2) is the somatomedin of T cell, stimulates T cell to enter cell division cycle, strengthens the killing activity of T cell, also can strengthen the activity of NK cell, promote the cell immune responses such as B cell secretion.There is the obstacle of cellular immunization in UC patient's body, immune system is in state of activation, and UC pathogenesis may reduce with serum IL-2 substantial connection.
IL-4 (IL-4) is the cytokine of II type T helper cells secrete, typical antiinflammatory and inhibitive ability of immunity cytokine, it can stimulate the propagation of activating B cell and T cell, plays an important role in adjustment humoral immunization, adaptive immunity and intestinal mucosa environment.
IL-10 (IL-10) is a kind of many cells source, multi-functional cytokine, participates in inflammatory reaction and immunoreation, is the inflammation and immunosuppressive factor of generally acknowledging at present.IL-10 is the emiocytosis of Th2 type, can suppress synthesis and the biological activity of the inflammation factor, is a kind of important cytokine modulators, plays an important role in the pathogenic process of ulcerative colitis in mucosal system.
Existing large quantifier elimination confirms the important function of inflammatory cytokine in ulcerative colitis at present.The change reflection body local of the active and MDA concentration of SOD or the inflammatory reaction situation of entirety and the ability of Antioxidation reaction in body.Radix Ranunculi Ternati polysaccharide may be a complicated mechanism to the protective effect of UC rat, and its concrete mechanism also needs to make further research.Although also not exclusively clear to its concrete mechanism of action at present, Radix Ranunculi Ternati polysaccharide has treatment and protective effect preferably to UC animal pattern, and it may play key player in the regulation process of inflammatory cytokine.
The safety of patent clinical practice of the present invention is higher, to can yet be regarded as a kind of good medicine in the Drug therapy for the treatment of ulcerative colitis, it has widened the new method for the treatment of ulcerative colitis, the untoward reaction simultaneously for occurring when patient solves prior art treatment ulcerative colitis.
Therefore, the novelty teabag that applicant provides Radix Ranunculi Ternati, Radix Ranunculi Ternati extract, Radix Ranunculi Ternati polysaccharide can be used in treating and/or preventing ulcerative colitis medicine aspect.
The invention discloses Radix Ranunculi Ternati extract treats and/or prevents ulcerative colitis medicine application in preparation, the preparation of described Radix Ranunculi Ternati extract comprises the following steps:
Get Radix Ranunculi Ternati medical material, pulverize, add medical material gross weight 6-12 water doubly, 70-100 DEG C is carried out lixiviate 2-3 time, each 1-3h, filters, and filtrate merges, and obtains Radix Ranunculi Ternati extracting solution.
The invention discloses Radix Ranunculi Ternati extract treats and/or prevents ulcerative colitis medicine application in preparation, the preparation of described Radix Ranunculi Ternati extract is preferably following steps:
Get Radix Ranunculi Ternati medical material, pulverize, add flooding 2 times, first time adds medical material weight 12 times of water 100 DEG C of lixiviates 3 hours, and second time adds medical material weight 10 times of water 100 DEG C of lixiviates 2 hours, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution.
The invention also discloses Radix Ranunculi Ternati polysaccharide treats and/or prevents ulcerative colitis medicine application in preparation, the preparation of described Radix Ranunculi Ternati polysaccharide comprises the following steps:
The heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 300-800g, adding concentrated solution weight 0.5-3 percent by volume is doubly that the ethanol of 30%-95% stirs, and leaves standstill 5h, and gained precipitation uses the 30%-95% washing with alcohol 2 times of weight of precipitate 5 times again, drying, obtains Radix Ranunculi Ternati polysaccharide.
Radix Ranunculi Ternati polyoses producing method disclosed by the invention is preferably following steps:
The heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 700g, the percent by volume adding concentrated solution weight 1 times be 95% ethanol stir, leave standstill 5h, gained precipitation uses 95% washing with alcohol 2 times of weight of precipitate 5 times again, dry, obtains Radix Ranunculi Ternati polysaccharide.
Radix Ranunculi Ternati extract and Radix Ranunculi Ternati polysaccharide become with pharmaceutically acceptable carrier combination is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
Radix Ranunculi Ternati provided by the invention, Radix Ranunculi Ternati extract, Radix Ranunculi Ternati polysaccharide is used for the treatment of and/or the novelty teabag of prevention of ulcerative colitis medicine aspect has the following advantages:
1, Radix Ranunculi Ternati, Radix Ranunculi Ternati extract, Radix Ranunculi Ternati polysaccharide obtain, safety non-toxic from plant Radix Ranunculi Ternati, can long-term taking.
2, find in " impact on ulcerative colitis mice " experiment, after Radix Ranunculi Ternati extract and the administration of Radix Ranunculi Ternati polysaccharide, IL-2 level in UC mice serum can be improved, reduce IL-10 level in serum." impact on ulcerative colitis in rats " experimental result shows, and the present invention can reduce IL-1 level in UC rat blood serum, IL-4 level in increasing serum, raises the content of SOD in rat intestine tissue, reduces the content of MDA.These data show that the present invention improves significantly to tools such as Ulcerative Colitis Model animal serum interleukin content, effectively can treat ulcerative colitis, therapeutic effect optimum is Radix Ranunculi Ternati polysaccharide, and Radix Ranunculi Ternati extract takes second place, but both all demonstrate significant therapeutic effect.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.
Embodiment 1:
Get 1kg Radix Ranunculi Ternati medical material, pulverize, add flooding 2 times, first time adds medical material weight 12 times of water 100 DEG C of lixiviates 3 hours, and second time adds medical material weight 10 times of water 100 DEG C of lixiviates 2 hours, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution.
Embodiment 2:
Get 1kg Radix Ranunculi Ternati medical material, pulverize, add flooding 3 times, first time adds medical material weight 12 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 10 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 8 times of water 70 DEG C of lixiviates 1 hour, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution.
Embodiment 3:
Get 1kg Radix Ranunculi Ternati medical material, pulverize, add flooding 2 times, first time adds medical material weight 12 times of water 100 DEG C of lixiviates 3 hours, and second time adds medical material weight 10 times of water 100 DEG C of lixiviates 2 hours, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution; Get the heating of Radix Ranunculi Ternati extracting solution and be concentrated into every L concentrated solution containing medical material 700g, the percent by volume adding concentrated solution weight 1 times be 95% ethanol stir, leave standstill 5h, gained precipitation uses 95% washing with alcohol 2 times of weight of precipitate 5 times again, drying, obtains Radix Ranunculi Ternati polysaccharide.
Embodiment 4:
Get 1kg Radix Ranunculi Ternati medical material, pulverize, add flooding 3 times, first time adds medical material weight 12 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 10 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 8 times of water 70 DEG C of lixiviates 1 hour, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution; The heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 300g, the percent by volume adding concentrated solution weight 0.5 times be 65% ethanol stir, leave standstill 5h, gained precipitation uses 65% washing with alcohol 2 times of weight of precipitate 5 times again, drying, obtains Radix Ranunculi Ternati polysaccharide.
Embodiment 5:
Get 1kg Radix Ranunculi Ternati medical material, pulverize, add flooding 3 times, first time adds medical material weight 12 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 10 times of water 70 DEG C of lixiviates 2 hours, and second time adds medical material weight 8 times of water 70 DEG C of lixiviates 1 hour, merge extractive liquid, filters, obtains Radix Ranunculi Ternati extracting solution; The heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 800g, the percent by volume adding concentrated solution weight 3 times be 30% ethanol stir, leave standstill 5h, gained precipitation uses 30% washing with alcohol 2 times of weight of precipitate 5 times again, dry, obtains Radix Ranunculi Ternati polysaccharide.
Effect experiment:
One, on the impact of ulcerative colitis mice
1. experiment material
1.1 animals: healthy SPF level kunming mice, 22-25g, buys from Guangxi Medical University's Experimental Animal Center (production licence number: SCXK osmanthus 2009-0002).
1.2 medicines and instrument
The embodiment of the present invention 1, embodiment 2, Mesalazine table (Jiamusi Lu Ling Pharmaceutical Co), dextran sulfate sodium (DSS, MPbio), mice IL-2Elisa test kit (Beijing Bo Ling section is bio tech ltd), mice IL-10Elisa test kit (Beijing Bo Ling section is bio tech ltd), CT15RT table-type high-speed refrigerated centrifuge (Shanghai Techcomp Instrument Ltd.).
2. experiment grouping
Get mice and be divided into 5 groups at random, often organize 10, male and female half and half, namely blank group, model group, positive controls, embodiment 1 group, embodiment 3 groups.
3. experimental technique
3.1 animal model
Except blank group, respectively organize the DSS of gavage 0.8ml50g/L, once a day, freely drink the DSS water of 20g/L, continuous 7 days simultaneously.Blank group gavage equal-volume normal saline, feeds drinking water.
3.2 medication
After each treated animal modeling every day gastric infusion 1 time, continuous 10 days, medication was as follows:
Blank group: gavage 10ml/kg distilled water;
Model group: gavage 10ml/kg distilled water;
Positive controls: gavage mesalazine medicinal liquid 45mg/ml, administration volume is 10ml/kg;
Embodiment 1 group: give embodiment 1 Radix Ranunculi Ternati extract, by crude drug gauge 100mg/kg, administration volume is 10ml/kg.
Embodiment 3 groups: give embodiment 3 Radix Ranunculi Ternati polysaccharide, by crude drug gauge 100mg/kg, administration volume is 10ml/kg.
3.3 Indexs measure
After last administration 24h, mice is plucked eyeball and get blood, the centrifugal 10min of 5000rpm/min, get Virus monitory IL-2, IL-10 level.
4, experimental result
Table 1 is group mice serum IL-2 and IL-10 level respectively
Note: compare with blank group, * P < 0.05, * * P < 0.01; Compare with model group, ☆ P < 0.05, ☆ ☆ P < 0.01; Compare with positive controls, △ P < 0.05, △ △ P < 0.01.
Table 1 result shows: compared with blank group, model group IL-2, IL-10 Cha different Xian Zhu ﹙ P < 0.01 ﹚, and modeling success is described.With model group IL-2 ratio, the IL-2 level of embodiment group and positive controls mice all obviously raises, wherein, embodiment 1, positive controls effect Xian Zhu ﹙ P < 0.05 ﹚, embodiment 3 effect is Xian Zhu ﹙ P < 0.01 ﹚ very.Compared with blank group IL-10, the IL-10 level of embodiment group and positive controls mice all obviously reduces, wherein, embodiment 1, positive controls effect Xian Zhu ﹙ P < 0.05 ﹚, embodiment 3 effect is Xian Zhu ﹙ P < 0.01 ﹚ very.
Experimental result shows: Radix Ranunculi Ternati extract provided by the invention, and particularly Radix Ranunculi Ternati polysaccharide effectively can improve UC mice serum IL-2 level, and reduce serum IL-10, effect is better than prior art.
Two, on the impact of ulcerative colitis in rats
1. experiment material
1.1 animals: healthy SD rat, 180-220g, buys from Guangxi Medical University's Experimental Animal Center (production licence number: SCXK osmanthus 2009-0002).
1.2 medicines and instrument
The embodiment of the present invention 1, embodiment 2, Mesalazine table (Jiamusi Lu Ling Pharmaceutical Co), 5%2, 4, 6-trinitro-benzene-sulfonic acid (TNBS) aqueous solution (Sigma), IL-1Elisa test kit (Beijing Bo Ling section is bio tech ltd), IL-4Elisa test kit (Beijing Bo Ling section is bio tech ltd), SOD test kit (Science and Technology Ltd. is built up in Nanjing), (Science and Technology Ltd. is built up in Nanjing to MDA test kit, CT15RT table-type high-speed refrigerated centrifuge (Shanghai Techcomp Instrument Ltd.).
2. experiment grouping
Rat adaptability is divided into 5 groups after raising one week at random, often organizes 10, male and female half and half, i.e. blank group, model group, positive controls, embodiment 1 group, embodiment 3 groups.
3. experimental technique
3.1 animal model
After the rat feeding 5d after grouping, water is can't help in 24h fasting, weigh, lumbar injection 10% chloral hydrate anesthesia (3.8ml/kg), one rubber tube (diameter 2mm, long 12cm) is inserted rat anus 8-10cm light and slowly, pushes TNBS solution (containing 2.5%TBNS and containing 50% ethanol), dosage is 2ml/kg, puts back in cage after modeling rat is inverted 1min.
3.2 medication
After each treated animal modeling the 3rd day starts gastric infusion, and continuous 10 days, one times/day, medication was as follows:
Blank group: gavage 10ml/kg distilled water;
Model group: gavage 10ml/kg distilled water;
Positive controls: gavage mesalazine medicinal liquid 45mg/ml, administration volume is 10ml/kg;
Embodiment 1 group: give embodiment 1 Radix Ranunculi Ternati extract, by crude drug gauge 100mg/kg, administration volume is 10ml/kg.
Embodiment 3 groups: give embodiment 3 Radix Ranunculi Ternati polysaccharide, by crude drug gauge 100mg/kg, administration volume is 10ml/kg.
3.3 Indexs measure
After administration last administration 24, rats by intraperitoneal injection 10% chloral hydrate (3.8ml/kg) is anaesthetized, abdominal aortic blood, the centrifugal 10min of 3000rpm/min, detect serum IL-1, IL-4 level by test kit description.Get after rat extracting blood and be about 8cm place colon 1cm from anus, prepare homogenate by test kit description, and detect SOD, MDA value.
4, experimental result
Table 2 respectively organizes IL-1 and IL-4 content in rat blood serum
Note: compare with blank group, * P < 0.05, * * P < 0.01; Compare with model group, ☆ P < 0.05, ☆ ☆ P < 0.01; Compare with positive controls, △ P < 0.05, △ △ P < 0.01.
Table 2 result shows, and compared with blank group, model group IL-1, IL-4 content difference be Xian Zhu ﹙ P < 0.01 ﹚ very, and modeling success is described; Compared with model group, positive controls, embodiment 1 and embodiment 3 groups of IL-1, IL-4 content differences are Xian Zhu ﹙ P < 0.01 ﹚ all very; Compared with positive controls, IL-1 and IL-4 content difference Xian Zhu ﹙ P < 0.05 ﹚ of embodiment 3.
The content of SOD and MDA in rat colon tissue respectively organized by table 3
Note: compare with blank group, * P < 0.05, * * P < 0.01; Compare with model group, ☆ P < 0.05, ☆ ☆ P < 0.01; Compare with positive controls, △ P < 0.05, △ △ P < 0.01.
Table 3 result shows, and compared with blank group, model group SOD, MDA content difference be Xian Zhu ﹙ P < 0.01 ﹚ very, and modeling success is described; Compared with model group, positive controls, embodiment 1 and embodiment 3 groups of SOD, MDA content differences are Xian Zhu ﹙ P < 0.01 ﹚ all very; Compared with positive controls, SOD and MDA content difference Xian Zhu ﹙ P < 0.05 ﹚ of embodiment 3.
Overall experiment effect display, the present invention effectively can treat ulcerative colitis, and therapeutic effect optimum is Radix Ranunculi Ternati polysaccharide, and Radix Ranunculi Ternati extract takes second place, but both all demonstrate significant therapeutic effect.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.
Claims (9)
1. Radix Ranunculi Ternati is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
2. Radix Ranunculi Ternati extract is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
3. purposes according to claim 2, is characterized in that described Radix Ranunculi Ternati extract is prepared by following steps and obtains: get Radix Ranunculi Ternati medical material, pulverizes, add medical material gross weight 6-12 water doubly, 70-100 DEG C is carried out lixiviate 2-3 time, each 1-3h, filter, filtrate merges, and obtains Radix Ranunculi Ternati extracting solution.
4. purposes according to claim 2, it is characterized in that described Radix Ranunculi Ternati extract is prepared by following steps and obtains: get Radix Ranunculi Ternati medical material, pulverize, add flooding 2 times, first time adds medical material weight 12 times of water 100 DEG C of lixiviates 3 hours, and second time adds medical material weight 10 times of water 100 DEG C of lixiviates 2 hours, merge extractive liquid, filter, obtain Radix Ranunculi Ternati extracting solution.
5. Radix Ranunculi Ternati polysaccharide is preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
6. purposes according to claim 5, it is characterized in that described Radix Ranunculi Ternati polysaccharide is prepared by following steps and obtains: the heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 300-800g, adding concentrated solution weight 0.5-3 percent by volume is doubly that the ethanol of 30%-95% stirs, leave standstill 5h, gained precipitation uses the 30%-95% washing with alcohol 2 times of weight of precipitate 5 times again, drying, obtains Radix Ranunculi Ternati polysaccharide.
7. purposes according to claim 5, it is characterized in that described Radix Ranunculi Ternati polysaccharide is prepared by following steps and obtains: the heating of Radix Ranunculi Ternati extracting solution is concentrated into every L concentrated solution containing medical material 700g, the percent by volume adding concentrated solution weight 1 times be 95% ethanol stir, leave standstill 5h, gained precipitation uses 95% washing with alcohol 2 times of weight of precipitate 5 times again, drying, obtains Radix Ranunculi Ternati polysaccharide.
8. Radix Ranunculi Ternati extract becomes with pharmaceutically acceptable carrier combination preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
9. Radix Ranunculi Ternati polysaccharide becomes with pharmaceutically acceptable carrier combination preparing the novelty teabag treated and/or prevented in ulcerative colitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022020.XA CN105497167A (en) | 2015-12-31 | 2015-12-31 | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511022020.XA CN105497167A (en) | 2015-12-31 | 2015-12-31 | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105497167A true CN105497167A (en) | 2016-04-20 |
Family
ID=55705726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511022020.XA Pending CN105497167A (en) | 2015-12-31 | 2015-12-31 | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105497167A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360149A (en) * | 2016-11-01 | 2017-02-01 | 耿明生 | Pangasius sutchi feed and preparation method thereof |
| CN108586627A (en) * | 2018-04-28 | 2018-09-28 | 上海中医药大学附属曙光医院 | Radix ranunculi ternati Thick many candies and polysaccharide component, preparation method and liver protection and immunoregulatory purposes |
-
2015
- 2015-12-31 CN CN201511022020.XA patent/CN105497167A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 缑旦: "《吾病自控自疗》", 28 February 2013, 内蒙古中医出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360149A (en) * | 2016-11-01 | 2017-02-01 | 耿明生 | Pangasius sutchi feed and preparation method thereof |
| CN108586627A (en) * | 2018-04-28 | 2018-09-28 | 上海中医药大学附属曙光医院 | Radix ranunculi ternati Thick many candies and polysaccharide component, preparation method and liver protection and immunoregulatory purposes |
| CN108586627B (en) * | 2018-04-28 | 2021-05-18 | 上海中医药大学附属曙光医院 | Radix Ranunculi Ternati crude polysaccharide and polysaccharide component, and its preparation method and application in protecting liver and regulating immunity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3560506A1 (en) | Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease | |
| Yi et al. | Intervention effects of lotus leaf flavonoids on gastric mucosal lesions in mice infected with Helicobacter pylori | |
| CN104042720B (en) | There is the Chinese medicine and application thereof of preventing and treating diabetes complicated depression | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN1857453A (en) | Chinese medicine composition for treating ulcerative colitis and its preparing method | |
| CN102389496B (en) | Chinese medical composition for treating hepatitis and preparation method thereof | |
| CN105031468B (en) | Fructus Alpinae Oxyphyllae extract with treatment chronic kidney disease effect and its application | |
| BR112014030570B1 (en) | extracts of wild thyme and use of these | |
| CN103655544B (en) | The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI | |
| CN115770251A (en) | Application of polysaccharide in preparing medicine for preventing and/or treating ulcerative colitis | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN103191175A (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN104435669B (en) | The Chinese medicine composition of the concurrent multiple organ dysfunction syndrome for the treatment of septic shock | |
| WO2013115534A1 (en) | Composition for preventing or treating multiple sclerosis | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN104411309B (en) | A Kela is scheduled on the purposes for preparing and being used to treat in the medicine of primary carcinoma of liver | |
| CN1435247A (en) | Chinese medicine preparation for treating lithiasis in urinary system and urethral infection, and preparing method thereof | |
| CN105168300A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| KR100506950B1 (en) | Immune stimulative constituents of ginseng saponins | |
| CN115463164B (en) | Preparation method of ephedra root ethyl acetate part, and medicine and application thereof | |
| CN115998779B (en) | Artemisia princeps polyphenol extract and preparation method and application thereof | |
| CN1772753A (en) | Chinese medicine active compound component for treating senile dementia and its prepn and use | |
| CN106924272B (en) | Application of methyl salicylate glucoside in preparation of medicines for preventing and/or treating systemic lupus erythematosus and complications thereof | |
| CN104771430B (en) | For treating the medicine of intestinal irritable syndrome | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160420 |